纵横研报
Ticker Detail

688336.SHG

¥53.78+2.81% 三生国健 Biotechnology
00Reports China 医疗健康
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
医疗健康 · 生物科技

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include Enbrel, a recombinant human type II tumor necrosis factor receptor-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation; and Enbrel, an anti-IL-17A humanized monoclonal antibody ambroxol injection for the treatment of moderate to severe plaque psoriasis. The company was founded in 2002 and is based in Shanghai, China.

MARKET 市值 45.63B CNY PE 15.4x 52W ¥31.87 – ¥65.85 EODHD · Q 2026-03-31 · 同步 2026-07-14
QUALITY PEG 营收 YoY 38.6% ROE 41.8% 营业利润率 44.0% 净利润率 68.9%
ANALYST 股息率 0.63%

暂无相关研报

数据库中已收录该标的的基本面数据,可发起一份定制研报。

CUSTOM RESEARCH · 定制研报 没找到完全契合的标的?让我们替你做一份。 告诉我们你关心的标的与偏好,1 个工作日内在站内上线。 开始定制